» Articles » PMID: 37157163

Pathogenicity and Virulence of

Overview
Journal Virulence
Specialty Microbiology
Date 2023 May 9
PMID 37157163
Authors
Affiliations
Soon will be listed here.
Abstract

, a polyphyletic Gram-positive taxon of bacteria, is classified purely by their ability to produce botulinum neurotoxin (BoNT). BoNT is the primary virulence factor and the causative agent of botulism. A potentially fatal disease, botulism is classically characterized by a symmetrical descending flaccid paralysis, which is left untreated can lead to respiratory failure and death. Botulism cases are classified into three main forms dependent on the nature of intoxication; foodborne, wound and infant. The BoNT, regarded as the most potent biological substance known, is a zinc metalloprotease that specifically cleaves SNARE proteins at neuromuscular junctions, preventing exocytosis of neurotransmitters, leading to muscle paralysis. The BoNT is now used to treat numerous medical conditions caused by overactive or spastic muscles and is extensively used in the cosmetic industry due to its high specificity and the exceedingly small doses needed to exert long-lasting pharmacological effects. Additionally, the ability to form endospores is critical to the pathogenicity of the bacteria. Disease transmission is often facilitated via the metabolically dormant spores that are highly resistant to environment stresses, allowing persistence in the environment in unfavourable conditions. Infant and wound botulism infections are initiated upon germination of the spores into neurotoxin producing vegetative cells, whereas foodborne botulism is attributed to ingestion of preformed BoNT. is a saprophytic bacterium, thought to have evolved its potent neurotoxin to establish a source of nutrients by killing its host.

Citing Articles

A novel single-domain antibody obtained from immune Bactrian camels against botulinum toxin type A using SPR-based screening method.

Hu N, Peng F, Jiang Z, Wang Z, Peng S, Xing C Heliyon. 2025; 11(4):e42616.

PMID: 40066047 PMC: 11891721. DOI: 10.1016/j.heliyon.2025.e42616.


Botulinum Neurotoxins as Two-Faced Janus Proteins.

Chimienti S, Di Spirito M, Molinari F, Rozov O, Lista F, DAmelio R Biomedicines. 2025; 13(2).

PMID: 40002825 PMC: 11853235. DOI: 10.3390/biomedicines13020411.


Advancements in the Pathogenesis, Diagnosis, and Therapeutic Implications of Intestinal Bacteria.

Lu D, Ma X, Tao K, Lei H Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996827 PMC: 11853859. DOI: 10.3390/cimb47020106.


Comprehensive analysis of antimicrobial resistance dynamics among broiler and duck intensive production systems.

Szoke Z, Fauszt P, Mikolas M, David P, Szilagyi-Tolnai E, Pesti-Asboth G Sci Rep. 2025; 15(1):4673.

PMID: 39920217 PMC: 11806100. DOI: 10.1038/s41598-025-89432-z.


Impact of Metabolites from Foodborne Pathogens on Cancer.

Mafe A, Busselberg D Foods. 2024; 13(23).

PMID: 39682958 PMC: 11640045. DOI: 10.3390/foods13233886.


References
1.
Fujinaga Y, Inoue K, Nomura T, Sasaki J, Marvaud J, Popoff M . Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett. 2000; 467(2-3):179-83. DOI: 10.1016/s0014-5793(00)01147-9. View

2.
Bonventre P, Kempe L . Physiology of toxin production by Clostridium botulinum types A and B. III. Effect of pH and temperature during incubation on growth, autolysis. and toxin production. Appl Microbiol. 1959; 7:374-7. PMC: 1057564. DOI: 10.1128/am.7.6.374-377.1959. View

3.
Godakova S, Noskov A, Vinogradova I, Ugriumova G, Solovyev A, Esmagambetov I . Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice. Toxins (Basel). 2019; 11(8). PMC: 6723419. DOI: 10.3390/toxins11080464. View

4.
Passaro D, Werner S, McGee J, Mac Kenzie W, Vugia D . Wound botulism associated with black tar heroin among injecting drug users. JAMA. 1998; 279(11):859-63. DOI: 10.1001/jama.279.11.859. View

5.
Duplantier A, Kane C, Bavari S . Searching for Therapeutics Against Botulinum Neurotoxins: A True Challenge for Drug Discovery. Curr Top Med Chem. 2016; 16(21):2330-49. DOI: 10.2174/1568026616666160413135630. View